PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study (PE-Prove)
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the PROMUS™ Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice
Sponsor: Boston Scientific Corporation
A observational or N/A phase clinical study on Coronary Heart Disease, this trial is completed. The trial is conducted by Boston Scientific Corporation and has accumulated 8 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Scientific Corporation
- Medidata Solutions
- Pharmaceutical Research Associates
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Hertogenbosch, Netherlands , Bad Berka, Germany , Bad Segeberg, Germany , Barcelona, Spain , Bergamo, Italy , Bonn, Germany , Caen, France , Cambridge, United Kingdom , Cardiff, United Kingdom , Darmstadt, Germany and 27 more locations